Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

A required part of this site couldn’t load. This may be due to a browser
extension, network issues, or browser settings. Please check your
connection, disable any ad blockers, or try using a different browser.